PRAC adopted an extension of indication for Gazyvaro for the treatment of patients aged 2 years and older with idiopathic nephrotic syndrome. (European Medicines Agency) - Oct 25, 2026 - Pharmacovigilance Risk Assessment Committee (PRAC) Minutes
of meeting on 31 Aug – 3 Sep 2026:
The update is based on final results from the Phase III INShore
(WA43380) study. Consequently, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2, and 6.6
of the SmPC were updated.
PRAC • Immunology
|